Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery

Stopped early · Early Phase 1

Conditions studied: Aortic Disease

In brief

This study hopes to determine the optimal antifibrinolytic dosing to decrease bleeding and blood transfusion after cardiac surgery without increasing adverse events

Key facts

Study ID

NCT01965730

Run by

University of Pennsylvania

People needed

8

Starts

2013-01-01

Expected to finish

2014-06-01

Last updated by the study team

2019-05-02

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to sign informed consent
• Elective cardiac surgery patients undergoing primary surgery involving circulatory arrest

You may not qualify if…

• Inability to sign informed consent
• Baseline hypercoagulable condition as defined in medical record
• Coronary disease with untreated lesions or recent coronary stent placement
• Severe renal dysfunction (ESRD) as documented in medical record

Where it is running

• University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.